'Some of them have accuracy that's close to zero': Experts unpack the promise and pitfalls of genetic tests aimed at consumers

Consumer genomic technologies—from direct-to-consumer polygenic tests to polygenic embryo selection—are rapidly entering the market but suffer from major scientific and ethical limitations, including low predictive accuracy for many traits, ancestry-specific portability problems, and lack of methodological transparency. Authors argue these shortcomings, alongside potential societal harms and inequality risks, increase the likelihood of regulatory scrutiny and reputational/legal exposure for companies operating in this space (the clearest technical example being height, which is ~80% heritable), making the sector one to monitor for policy-driven headwinds rather than near-term revenue surprises.

Analysis

Market Structure: Winners are clinical genomics infrastructure and regulated diagnostic providers (e.g., Illumina - ILMN, large diagnostics arms of Roche/RHHBY) that supply sequencing, analytics and clinical-grade polygenic risk score (PRS) integration; losers are pure-play consumer genetics and embryo-selection startups that monetize low‑predictive polygenic claims (e.g., 23andMe - ME, small IVF genetic boutiques). Expect pricing power to shift toward regulated lab services and enterprise software that can demonstrate clinical utility; consumer DTC price elasticity will increase if regulators force validation, compressing gross margins for unvalidated players.

Risk Assessment: Tail risks include rapid regulatory clampdowns (FDA/Federal guidance or EU rulings) within 3–12 months that could remove DTC claims or require clinical validation, causing >30% revenue shock for exposed firms. Hidden dependencies: research-tier PRS portability across ancestries—if new studies (within 6–18 months) document poor portability, litigation and reputational costs could cascade into class-action risk and insurer refusals to reimburse.

Trade Implications: Near-term (0–6 months) favor hardware/clinical service exposure and hedged short exposure to consumer DTC names; options implied vol should rise on regulatory headlines—buy ~6–12 month puts on headline DTC names and buy 12–24 month LEAPS calls on select sequencing/instrumentation names. Reallocate toward payor/enterprise adopters (UnitedHealth - UNH) and fertility-benefit managers (Progyny - PGNY) with modest position sizes; expect secular re-rating over 12–36 months if clinical use cases prove cost-effective.

Contrarian Angles: Consensus underestimates how fast clinical demand for validated PRS in cardiology/oncology could grow once payors see 5–10% attributable cost reduction; equally, the market may be overpricing embryo-selection hype—small embryo pools (often <6 embryos) cap expected benefit, so valuations of specialist embryo-selection vendors look vulnerable. Historical parallel: early internet consumer hype followed by consolidation into enterprise-focused businesses; expect similar contraction and selective consolidation over 2–4 years.

Key Decisions for Investors

• Establish a 2–3% long position in Illumina (ILMN) with 12–24 month horizon; complement with purchase of 18-month LEAPS (buy Jan 2028 85–95 strike calls depending on basis) to capture clinical sequencing secular growth if payors adopt PRS in cardiology/oncology.
• Initiate a 1–2% short or put spread on 23andMe (ME) via buying 3–6 month at-the-money puts (or short stock if options illiquid); if FDA issues draft DTC regulation within 90 days, be prepared to add to size as >20% downside is plausible on enforceable restrictions.
• Pair trade: go long Progyny (PGNY) 1–2% and short a consumer DTC basket (top 2–3 names by market cap) 1–2% to express fertility-services upside vs DTC consumer-testing downside; target exit or rebalance at 6–12 months or on regulatory clarity.
• Buy defensive exposure: purchase 6–12 month out-of-the-money put protection (5–7% notional) on healthcare/biotech core holdings if a regulatory guidance is published within 90 days; if no guidance in 90 days, reduce protection to 2–3% notional.
• Monitor triggers: (a) FDA docket and HHS guidance for DTC genetic tests and embryo-selection language (actionable within 30–90 days), (b) major insurer pilot results on PRS-driven interventions (UNH/insurers reporting within 6–12 months), and (c) high‑impact ancestry/portability papers (academic preprints) over next 6 months—adjust positions if any show clinically meaningful validation or debunking (>10% implied move).